Slides
Page 1
CHRYSO COP C CHRYSOS CORPORATION Assays at the speed of light Faster , more accurate gold analysis FY26 Financial Results 11 August 2026 Dirk Treasure , Managing Director and CEO Brett Coventry , CFO
Page 2
Important notice CHRYSOS CORPORATION LIMITED | 2 The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) (“Chrysos” or the “Group") and is general background information about Chrysos’ current activities as at the date of this presentation. The information is given in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with the Company’s other announcements to ASX. Information in this presentation, including forecast financial information, should not be considered advice or a recommendation to current shareholders, investors or potential investors, in relation to holding, purchasing or selling securities in the Company, and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. Forward-looking statements This presentation may contain statements that are, or may be deemed to be, forward-looking statements, for example statements that use words such as “may”, “will”, “would”, “could”, “expects”, “intends”, “anticipates”, and other similar words that involve risks and uncertainties. You should not place undue reliance on such forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this document, are expected to take place. No person who has made any forward-looking statements in this document has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this document, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company. This presentation also contains references to certain intentions, expectations and plans of the Company. These intentions, expectations and plans may or may not be achieved. They are based on certain assumptions which may not be met or on which views may differ. This presentation may contain information that has been derived from publicly available sources that have not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of this information. Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. To the maximum extent permitted by law, Chrysos, its subsidiaries and their respective officers, employees, agents and consultants, and any other person involved in the preparation of this presentation, disclaim all liability and responsibility, including, without limitation, any liability arising out of fault or negligence, for any direct or indirect loss which may arise from or be suffered through use or reliance on anything contained in, or omitted from, this presentation.
Page 3
FY26 Results presented by Managing Director and CEO, Dirk Treasure, and CFO, Brett Coventry Agenda CHRYSOS CORPORATION LIMITED | 3 01 FY26 highlights Slides 4–8 02 Financial performance Slides 9–17 03 Growth opportunity Slides 18–23 04 FY27 guidance and outlook Slides 24–30 05 Appendices Slides 31–40
Page 4
Achieved higher end of FY26 Revenue and EBITDA guidance Financial and operating highlights Total Revenue • +33% growth YoY versus FY25 ($66.1m) • MMAP Revenue of $62.5m (+12% YoY), AAC Revenue of $25.5m (+153% YoY) • Reflects ongoing global adoption of PhotonAssayTM and strong utilisation $88.1m EBITDA • +68% growth YoY FY25 ($16.1m) • Improved EBITDA Margin of 31% compared to 24% in FY25 • Economies of scale and increased utilisation driving profitability $27.2m Funding position • Operating cash-flow positive FY26: $17.9m net inflow • Funding position includes $25.9m cash and $140m in undrawn debt, bolstered by a refinanced debt facility arrangement • Well-funded to support increased manufacturing cadence of PhotonAssay units $165.9m Deployed units • Seven units deployed in FY26 and six units currently deploying • 24 new lease agreements signed during FY26, with a further four signed post- period, bringing total contracted units to 87 (including post-period leases) • 11.3 million samples processed during FY26, up 67% on FY25 46 CHRYSOS CORPORATION LIMITED | 4
Page 5
Continued conversion to PhotonAssay and industry activity driving samples PhotonAssay sample volumes PhotonAssayTM Samples Analysed Quarterly Activity Commentary Revenue ■ FY26 revenue of $88.1m, comprised of $62.5m MMAP and $25.5m AAC ■ AAC represented 29% of revenue, up from 15% in FY25, reflecting the strength of Chrysos’ business model, which captures upside during increased industry activity ■ Revenue at the top end of guidance, underpinned by consecutive record sample volumes and achieved in spite of forex headwinds ■ Sustained PhotonAssayTM demand - monthly throughput surpassed a record 1m samples and has held above that level each month since March 2026 ■ Increased monthly throughput, with year-on-year sample growth of 67% ■ Industry outlook remains constructive, supported by an elevated gold market, strong exploration activity and production outlook ■ New record of 1.1m+ samples achieved in July 2026 CHRYSOS CORPORATION LIMITED | 5 - 500 1,000 1,500 2,000 2,500 3,000 3,500 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Sample Volume (Thousands) Samples Processed (Quarterly)
Page 6
Rising utilisation, fleet expansion and software-led throughput gains are driving record sample volumes Sample volumes scaling ahead of the fleet PhotonAssayTM Samples Analysed Quarterly Activity Commentary CHRYSOS CORPORATION LIMITED | 6 ■ Quarterly PhotonAssay sample volumes grew~2.4× over the last 24 months, from ~1.3m in Q4 FY24 to a record ~3.1m samples in Q4 FY26 ■ Sample growth is outpacing the fleet with hub-lab PhotonAssay utilisation increasing from 41% during FY25 to 59% during FY26. Chrysos’ global hub labs can support further PhotonAssay demand, particularly in EMEA and the Americas: ■ Americas utilisation 27% (FY25) 38% (FY26) ■ APAC utilisation 56% (FY25) 79% (FY26) ■ EMEA utilisation 30% (FY25) 44% (FY26) ■ Chrysos deployed 11 units during FY25, seven during FY26 and is currently deploying six units, broadening our global footprint and supporting demand for PhotonAssay capacity ■ PhotonAssay upgrades are increasing per-unit capacity by 10-20% with minimal capital costs. Several units repeatedly demonstrate capacity of almost 50,000 samples per month (nameplate capacity is 40,000pm) 1.3 1.6 1.7 2.2 2.5 2.8 2.9 3.1 0 1 2 3 4 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Samples (millions)
Page 7
Strengthening relationships with key miners and laboratories Executing on our global PhotonAssayTM roll out 46 Units Deployed1 FY26 Activity Seven units deployed in FY26, bringing total deployed units to 46: Three units deployed with ALS across Australia and Canada One unit deployed for MSA at Grand Falls-Windsor, Canada First unit deployed to South America with Bureau Veritas (BV) in Chile Unit deployed to Norseman, Australia with ITK The first next-generation “XN” unit deployed at SGS Perth Redeploying one Ghanaian unit, demobilised and in transit to Morocco 24 new lease agreements and four post-period, contracted units total 87: Expansion of ALS relationship with four recent agreements in new regions Expanding global footprint with SGS with an upcoming deployment to Canada Expansion of the BV relationship with a unit currently deploying in Kalgoorlie, and two further contracts signed post period for Peru and Mexico Direct-to-mine focus supported by lease agreements with: A second Newmont unit at their Merian mine, Suriname Acrux Gold’s Cononish Project, Scotland Alkane’s Bjorkdal mine, Sweden, to be operated by CRS Pantoro’s Norseman mine, Australia, operated by ITK Allied Gold’s Sadiola mine, West Africa and the Kurmuk mine in Ethiopia Two additional contracts post period with an Australian gold miner High-quality, growing pipeline will support accelerated deployments 1. As of 30 June 2026 CHRYSOS CORPORATION LIMITED | 7
Page 8
Increasing utilisation supports sustained gross profit per unit Targeted sales strategy Quarterly PhotonAssayTM samples analysed Direct to Mine Deployments bring PhotonAssayTM technology directly to major gold producers, improving mining efficiency with high-quality data. Our Technical Services Team of metallurgists and geologists offers value-added services - ore body analysis, multi-sample testing, and gold, silver, and copper applications - to maximise the benefits of PhotonAssay TM and drive incremental volume. Laboratory partnerships support adoption by local miners and explorers. Sales Managers engage local miners and explorers near hub-and- spoke labs, driving sample volume and PhotonAssay TM adoption. Higher utilisation drives gross profit, EBITDA margin, and further lab adoption. Hub & Spoke Deployment Strategy Minesite Deployment Strategy PhotonAssayTM deployed direct to the mine site PhotonAssayTM deployed to hub and spoke laboratories - Miner adoption supported via endorsement by major lab companies - Impacted by macro trends with potential volatility in sample volumes - Samples span the breadth of a miner; exploration, mining, processing - Strong relationships with the miner and upside volume potential Two-pronged sales approach CHRYSOS CORPORATION LIMITED | 8 - 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 Laboratory Mine Site
Page 9
[Insert] FY26 Financial Summary
Page 10
Continued adoption of PhotonAssayTM and increased industry activity continue to drive growth Diversifying regional revenues Revenue1 by Region CHRYSOS CORPORATION LIMITED | 10 ■ Revenue1 of $88.1m, up 33% YoY (FY25: $66.1m), driven by continued adoption of PhotonAssayTM technology and elevated industry activity ■ Growth was delivered across all three regions, with APAC up 70% to $39m, the largest contributor to FY26 growth, driven by three new units and growth of $11.4m in AAC ■ International revenue rose 14% to $49.2m, or 56% of Group revenue, Americas up 28% to $23.4m as the installed base scaled, and EMEA up 4% to $25.8m, consolidating two years of substantial growth ■ Group revenue has almost doubled since FY24 ($45.4m to $88.1m), underpinned by an increasingly diversified geographic base Revenue diversification reflects increased global market penetration 1. Revenue includes operating lease and other revenue $0 $10,000 $20,000 $30,000 $40,000 $50,000 $60,000 $70,000 $80,000 $90,000 $100,000 FY24 FY25 FY26 Revenue Region ('000's AUD) APAC EMEA Americas 33%
Page 11
$- $10,000 $20,000 $30,000 $40,000 $50,000 $60,000 $70,000 $80,000 $90,000 $100,000 FY25 FY26 $'000 Minimum Monthly Assay Payment Additional Assay Charges Other Revenue / Income +33%1 MMAP provides a stable revenue floor, while AAC captures accelerating upside from rising utilisation Predictable base revenue with accelerating upside MMAP, AAC and Other Revenue CHRYSOS CORPORATION LIMITED | 11 ■ Minimum Monthly Assay Payments (MMAP) provide predictable and sustainable minimum revenue underpinning the business ■ FY26 MMAP of $62.5m, up 12% on FY25 ($55.9m) ■ MMAP comprised 71% of FY26 revenue ■ Additional Assay Charges (AAC) capture per-sample revenue above MMAP, directly linked to customer utilisation ■ FY26 AAC of $25.5m, up 153% on FY25 ($10.1m) ■ AAC contributed 29% of FY26 revenue, highlighting the increasing contribution of utilisation-led, per-sample revenue Further AAC growth expected to continue, amid an elevated gold market and record sample volumes 1. Growth on YoY MMAP/AAC/other revenue
Page 12
$'000 FY25 FY26 % change Revenue 65,990 87,999 Revenue from consumables 122 111 Total Revenue 66,112 88,110 33% PhotonAssayTM expenses (15,671) (21,264) 36% Other costs (18) (52) Gross Profit 50,423 66,794 32% Employee expenses (23,624) (27,310) Travel & marketing costs (2,484) (2,690) Admin & other expenses (8,181) (9,606) Total Operating Expenses (34,289) (39,607) 18% Insurance recovery income - 886 Impairment expense - (906) EBITDA 16,134 27,168 69% D&A (15,261) (21,386) EBIT 873 5,782 Net finance, interest & other income (3,753) (7,578) Loss before income tax (2,880) (1,796) Income tax (5,343) 3,587 NPAT (8,223) 1,790 Other comprehensive income 4,268 (5,421) Total comprehensive loss (3,955) (3,631) EBITDA margin growing with scale and utilisation Revenue & profitability CHRYSOS CORPORATION LIMITED | 12 1 2 3 45 6 1 2 3 Total Revenue of $88.1m: +33% YoY, reflecting continued global adoption of PhotonAssay , strong gold market conditions and record utilisation across the deployed fleet: • Dependable MMAP Growth: Consistent increase in MMAP in line with expanding deployments, demonstrating the reliability and strength of Chrysos’ business model • Additional Assay Charges Driving Revenue: Strong gold market conditions and continued market adoption driving materially higher utilisation across the deployed fleet PhotonAssay Operating Expenses of $21.3m: +36% YoY — comprising fleet maintenance of $11.4m and direct operating labour of $9.9m; growth reflects a larger deployed fleet and record activity levels, with direct costs held broadly stable at ~24% of revenue Gross profit up 32% to $66.8m: (FY25: $50.4M), with margins steady as PhotonAssay cost growth broadly tracked revenue growth Operating Expense Growth of just 18%: — operating expenses of $39.6m grew well below the 33% revenue increase; operating costs fell from ~52% to 45% of revenue, evidencing continued scale benefits EBITDA Growth of 68% YoY: Increased to $27.2m, with the EBITDA margin expanding from 24% to 31% as revenue growth continued to outpace operating cost growth Net Profit After Tax (NPAT): Improvement in underlying earnings and global tax position 4 5 6
Page 13
Reported results absorbed a material FX headwind, yet still delivered at the top of guidance Foreign exchange impact on FY26 result Reported vs constant currency (A$m) CHRYSOS CORPORATION LIMITED | 13 ■ FY26 guidance was set in August 2025 on constant-currency FX assumptions, with approximately 55% of Group revenue exposed to non-AUD currencies ■ Prior guidance positioned Total Revenue and EBITDA toward the upper end of their ranges ($80–90m and $20–27m respectively) ■ FY26 delivered at the upper end of guidance: Total Revenue of $88.1m and EBITDA of $27.2m ■ On a constant-currency basis (August 2025 assumptions), the result equates to ~$91.0m revenue and ~$30.2m EBITDA ■ The FY26 performance absorbed ~$2.9m revenue and ~$3.0m EBITDA FX translation headwind while still delivering at the top of the range, with improving EBITDA conversion Underlying performance exceeded guidance — reported results absorbed a ~A$3m FX headwind we actively managed 1. Guidance set in August 2025 with constant currency assumptions (AUD:USD 0.639, AUD:CAD 0.884, AUD:GBP 0.479, AUD:NZD 1.079). 88.1 27.2 91.0 30.2 0 20 40 60 80 100 Total Revenue EBITDA Reported Constant currency
Page 14
Strong unit metrics across deployed units Unit metrics and financial leverage Unit Metrics1 CHRYSOS CORPORATION LIMITED | 14 Consistent 70-80% gross profit margins sustained across FY24, FY25 and FY26, reflecting durable revenue and disciplined unit cost FY26 unit margins held firm even as direct employee costs absorbed short- term incentives (STI) at full achievement of performance, versus partial in prior years Cost control supported by hubbing strategy and greater in-house maintenance by Chrysos team members, continuing to reduce reliance on third parties Revenue underpinned by MMAP with FY26 MMAP exit rate of $65.9m AAC per unit more than doubled in FY26, supported by broader industry activity and growing market adoption, evidencing revenue upside Five units installed in May/June FY25 ramping up revenues from deployment Some underperforming units now close to or exceeding committed MMAP volumes allow for future AAC upside High gross margins of between 70-80% achieved across FY24, FY25 and FY26 1. Based on the average of all deployed units during the period. - 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000 Revenue per unit Cost per unit Revenue per unit Cost per unit Revenue per unit Cost per unit FY24 FY25 FY26 MMAP per unit Cost per unit
Page 15
Operating leverage translating to cash generation Cash flow summary CHRYSOS CORPORATION LIMITED | 15 EBITDA Growth: EBITDA of $27.2m - a 68% increase from FY25 driven by continued fleet expansion, record sample volumes and the increasing contribution of utilisation-led AAC Margin Expansion: EBITDA margin expanded from 24% to 31% YoY, reflecting the operating leverage inherent in our lease model as the deployed fleet scales Strong Operating Cashflow: Increased to $17.9m, up 103% on FY25, reflecting accelerating cash generation. Driven by materially higher EBITDA, effective capital management, improved cash conversion and the ongoing scaling of Chrysos' global operating platform Strategic Growth CAPEX: $36.3m invested in global fleet expansion, the core driver of future recurring revenue. Total capital expenditure of $41.0m includes $0.6m sustaining capex and R&D (below) Continued R&D Investment: ~$4.1m R&D ($2.0m capitalised plus $2.0m work-in-progress), directed toward infrastructure and next- generation PhotonAssay development 1 2 3 4 $000's FY25 FY26 EBITDA 16,134 27,168 Non-Cash Items 4,790 5,280 Changes in Working Cap (29,756) (14,519) Operating Cash flow 8,832 17,929 Sustaining Capex (3,164) (648) Growth Capital Expenditure (60,082) (36,308) Work-in-progress R&D (2,908) (2,041) Capitalised R&D (2,568) (2,014) Total CAPEX (68,722) (41,011) Free Cash flow before financing (59,890) (23,082) 1 2 4 3 5
Page 16
$'000 30-Jun-25 30-Jun-26 Assets Cash and cash equivalents 21,520 25,892 Trade and other receivables 27,707 33,123 Other current assets (incl prepayments) 13,484 15,764 International withholding tax 1,440 3,534 Non-current assets 200,160 228,157 Total Assets 264,310 306,471 Liabilities Trade and other payables 34,033 34,723 Other current liabilities 7,052 7,456 Loans and borrowings 17,414 59,445 Other non-current liabilities 7,509 7,169 Total Liabilities 66,008 108,793 Net Assets 198,302 197,678 Issued capital 214,261 215,370 Accumulated losses (21,945) (18,684) Reserves 5,986 992 Total Equity 198,302 197,678 Strong Balance Sheet to Support Growth: Strong balance sheet maintained, with net assets of $197.7m (FY25: $198.3m); total assets $306.5m; $25.9m cash. Supporting continued global scale-up of the PhotonAssay platform Increased Trade Receivables: Receivables growth $33.1m (FY25: $27.7m), +20%, reflecting increased activity and disciplined collections contributing to positive operating cash flow Growth in Non-Current Assets: Non-current assets will continue to grow, $228.2m (FY25: $200.2m), +14%, driven by the expanding PhotonAssay fleet, aligning with the company’s long-term strategy for increased market penetration and enhanced service delivery Debt Facility Utilisation: $60.0m drawn of a new $200m syndicated facility ($140m undrawn), funding fleet expansion with ample headroom for future deployments Strong balance sheet provides a solid platform to sustain growth Balance sheet CHRYSOS CORPORATION LIMITED | 16 1 2 3 4 1 2 3 4
Page 17
Strategic funding to support growth CHRYSOS CORPORATION LIMITED | 17 Increased Funding Position 0 25 50 75 100 125 150 175 200 Existing Increased Cash Available Debt $AUD Millions +$105m Strengthened funding capacity $200m Syndicated Facility ■ Refinanced corporate facilities via new three-year A$200m syndicated facility with three domestic financiers ■ Shift from asset-based financing to a corporate-style structure, designed for greater operational flexibility ■ Funding headroom +$105m, reflects lenders' confidence in Chrysos' customer base and long-term contracted revenue ■ Improved pricing and covenant package relative to former facility arrangements ■ Proceeds drawn to extinguish the existing asset-based facility Growth Enablement Through FY27 and Beyond ■ $140m in undrawn debt supports manufacturing and global deployment of PhotonAssay units ■ Underpins return to target manufacturing cadence of 18 units/year
Page 18
[Insert] Strategy
Page 19
Expanding market penetration and growing engagement with the world’s leading miners Growing PhotonAssay technology adoption ● FY26: Northern Star became our first mining client to use PhotonAssayTM as its primary analysis technique across all major sites ● June 2026: Bureau Veritas deployed our first units to Chile, South America ● November 2025: SGS, Perth, installed Chrysos’ first next generation “XN” unit ● August 2025: Bureau Veritas entered into its first PhotonAssayTM lease. Chrysos now has all four major global geochemistry labs promoting PhotonAssayTM ● May 2025: Newmont Corporation, the world’s leading gold miner, signed an MSA to use PhotonAssayTM for its gold mining projects ● May 2025: OceanaGold installed a PhotonAssayTM unit directly to its Macraes mine site in New Zealand Source: S&P Global Metals and Mining Database Top 20 gold producing companies by 2025 production Significant market penetration with 80% of the top 20 gold producers engaged CHRYSOS CORPORATION LIMITED | 19 Recent endorsements Gold Fields 6% Northern Star 5% Newmont 14% Agnico Eagle 9% Barrick 8% Kinross 6% Majority ProjectsTestwork and other engagement Future potential Active User
Page 20
Vision: to become the world’s leading provider of innovative assay services and technologies The Opportunity CHRYSOS CORPORATION LIMITED | 20 Convert gold mining projects in all key mining hubs to PhotonAssayTM Focus on improved customer outcomes to drive sample volumes Strategic partnerships with customers that have capacity for larger unit numbers Comparative pricing approach for efficient market penetration Drive profitability & growth, with a lease model and a high return on capital Growth opportunities beyond gold Total Addressable Market (TAM)1 1. As of 30th June 2026 200 410 0 100 200 300 400 500 600 700 Deployed Units TAM Off-site Laboratories On-site Laboratories 610 Sites 34 Active PA Sites 46 Deployed PA Units ~8% market share offers considerable upside
Page 21
Disseminated market, now with a presence in every region Chrysos growth strategy CHRYSOS CORPORATION LIMITED | 21 19% 23% 32% 1. Gold mines producing 40,000 pa or more annually (as of 2024) Percentage of miners within total addressable market 410 + large1 global gold mines offer substantial growth opportunity 13% 13% ■ Established global footprint for PhotonAssayTM technology supported by major global laboratory partners ■ Bureau Veritas agreement supports Chrysos’ deployment into South America, with post-period contract signed for Peru, establishing a beachhead in the region ■ Chrysos’ disseminated target market is well-serviced via established hubs without incurring substantial expansion costs ■ Strategic hubs maximise operational synergies, leading to lower operational costs and sustained gross profit margins
Page 22
Unlocking further market opportunities PhotonAssayTM beyond gold Core market focus → Additional revenue streams → Near-term R&D → Long-term potential → Non-gold momentum Current / Core PhotonAssay applicability and market focus Commercially Available Detectable Elements Increased revenue per sample & sample volume Optimising Mine Sites Concurrent moisture & solution analysis New elements via energy tuning – ~half of the periodic table addressable; two applications in development • Base & energy metals • Rare earths • Neutron analysis (bulk) • X-ray fluorescence (XRF) • Automated sample prep Non-gold volumes +83% over 18 months CHRYSOS CORPORATION LIMITED | 22 132 156 177 173 219 242 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Non-gold samples (’000) Silver Copper High-grade Total
Page 23
Fleet growth, production-linked volumes and a supportive gold price underpin durable earnings CHRYSOS CORPORATION LIMITED | 23 Driver 1 — Fleet scaling Deployments support ~2x fleet over three years ■ Contracted book and deployment pipeline underpin fleet growth ■ Pipeline spans manufacturing, shipping, installation and commissioning ■ Doubling the installed base expands recurring- revenue capacity Driver 2 — Resilient demand Industry maintaining elevated assay cadence ■ Structural shift to PhotonAssay sustaining elevated sample volumes ■ Elevated gold price supports strong customer activity ■ Multi-commodity expansion broadens the demand base Driver 3 — Lower earnings volatility Volumes linked to production, not exploration ■ Revenue tracks processed production volumes, not exploration cycles ■ Adoption is sticky — reverting to slower, destructive, lead-based fire assay is an unattractive downgrade ■ MMAP contracts provide a recurring revenue floor A larger fleet, production-linked volumes and a supportive market underpin a resilient, lower- volatility earnings outlook Resilient multi-year growth outlook
Page 24
[Insert] FY27 Guidance and Outlook
Page 25
CHRYSOS CORPORATION LIMITED | 25 Pillar 1 — Improving revenue visibility Contracted pipeline continues to strengthen ■ 24 new lease agreements signed during FY26 ■ 87 contracted units supports (41 to deploy) ■ Six units currently being deployed ■ Direct-to-mine deployments expanding ■ Relationships with the world’s biggest miners and labs Pillar 2 — Existing fleet continues to mature Utilisation growth complements deployments ■ Record sample volumes ■ Four consecutive months above one million samples ■ Expanding EBITDA margin ■ AAC reflects increasing utilisation ■ Demonstrated capacity improvements Pillar 3 — Execution capability strengthened Operational capability expanded during FY26 ■ Manufacturing cadence restored ■ Strong funding position ■ Next Generation PhotonAssayTM progressing ■ Global deployment capability expanded ■ Increasing use of non-gold analysis FY26 success derisks FY27 Broad-based industry acceptance across customers, partners and geographies FY27 guidance is supported by a larger contracted fleet, increasing deployment visibility, a mature operating platform and co ntinued utilisation growth across the existing installed base
Page 26
Global fleet supporting future growth PhotonAssayTM deployments Total PhotonAssayTM Units 54 → 59 + 5 Units manufactured since May 2026 update Deployed PhotonAssayTM Units 44 → 46 + 2 Inclusive of one Ghanaian unit demobilised Contracted PhotonAssayTM Units 83 → 87 + 4 From May 2026 trading update to Aug 2026 PhotonAssayTM deployment pipeline Pre-ship or stored 3 Aug 2026 April: 5 | Δ - 2 Shipping to site 1 Aug 2026 April: 4 | Δ - 3 Awaiting installation 5 Aug 2026 April: 4 | Δ - 1 Installing 6 Aug 2026 April: 1 | Δ + 5 ◂ Furthest from operational Operational Deployed Aug 2026 April: 44 | Δ + 2 CHRYSOS CORPORATION LIMITED | 26 46 Nine units available (pre-shipping, shipping and awaiting installation) – supporting near term deployments Six units currently deploying into customer sites Five PhotonAssayTM units manufactured since May 2026 trading update One redeployment currently underway of the MSA Obuasi unit, which is being redeployed into Morocco A further two units deployed since the May 2026 trading update Redeployments 1 Aug 2026 April: 0 | Δ +1
Page 27
Forecastable Revenue Model FY27 Guidance CHRYSOS CORPORATION LIMITED | 27 FY27 Guidance: ■ Total Revenue range of between $108m and $118m ■ EBITDA range of between $35m and $42m Note: Guidance set in August 2026 with constant currency assumptions (AUD:USD 0.6945 AUD:CAD 0.9627, AUD:GBP 0.522 AUD:EUR 0.6018 AUD:NZD 1.1923 AUD:GHS 8.541)
Page 28
Achieved upper end of FY26 guidance, and well-funded to support future growth FY26 in summary CHRYSOS CORPORATION LIMITED | 28 Financial ■ Revenue of $88.1m, up 33% on FY25 ■ 68% growth in EBITDA to $27.2m Operational ■ 46 PhotonAssay TM units currently deployed ■ Seven units deployed in FY26 with a strong sales and manufacturing pipeline ■ 24 new lease agreements signed in FY26 and four post-period, totaling 87 contracted units ■ Record (+67% YoY) sample volumes Corporate ■ $25.9m cash and $140m in undrawn debt to fund growth. Total funding position of $165.9m ■ Positioned for growth in FY27 and beyond with a targeted manufacturing cadence of 18 units/year
Page 29
PhotonAssayTM is the mining industry’s most innovative assaying solution The Chrysos investment proposition Non-discretionary spend for miners Long-term contracts Lease model provides secure revenue with upside potential Competitive fee-per-sample model Strong patent protection 70-80% gross margin Delivering faster, safer, more accurate and environmentally-friendly gold analysis CHRYSOS CORPORATION LIMITED | 29
Page 30
Thank you For more information, please visit chrysoscorp.com or contact us at investors@chrysoscorp.com
Page 31
[Insert] Appendix: About Chrysos
Page 32
The outcome of 20+ years of research and development CHRYSOS CORPORATION LIMITED | 32 2001 2012 2017 2018 2019 2020 2021 2022 PhotonAssayTM Development CSIRO begins development of PhotonAssayTM technology Prototyping Commences CSIRO builds PhotonAssayTM prototype in Canada Prototype Complete 1st PhotonAssayTM Max unit Chrysos Corporation Chrysos Corporation formed to commercialise PhotonAssayTM First unit Commercialised MinAnalytical laboratory Perth JORC and NI43-101 Companies cite PhotonAssayTM data in market announcements More Units Commissioned 2nd unit commissioned for MinAnalytical Industry Uptake Accelerates 3rd unit installed for MinAnalytical as industry adoption of PhotonAssayTM grows Unit Commissioned for Miner 4th unit supplied to Kirkland Lake Gold Chrysos reports 500,000 commercial assays performed Industry Recognition & Awards SA Premier’s Award for Energy & Mining – productivity Improvement category KCA Award for Best Research Commercialisation New Customer Announcements Barrick Bulyanhulu in Tanzania contracts MSALABS and PhotonAssayTM New Unit Deployments Further units to be deployed in Australia & North America Increased Manufacturing Chrysos increases manufacturing capacity Strong Customer Penetration PhotonAssayTM now used by 3 of the top 4 global laboratory services providers (ALS, Intertek and SGS) Prime Minister’s Award PhotonAssayTM team wins Prime Minister’s Award for Innovation 2023 International deployment continues Established Canadian & African hubs Global Partnership Up to 13 units to be deployed for Barrick Gold and MSALABS 2024 4th Continent established One unit deployed in England Our commercialisation journey First USA Deployment Barrick-Newmont NGM operation 2025 Newmont MSA To use PhotonAssayTM across its operations 2026 South America’s first Deployment Bureau Veritas deployed a unit in Chile XN Generation Unit Upgrade Rolled out the first PhotonAssayTM XN Generation unit
Page 33
Step 3 Automated reporting Sample can be retained for future assay or safely disposed of if no longer required 70 samples per hour 40,000 samples per month Step 1 The crushed sample (2-3 mm) is loaded into jars and scanned into unit by operator Step 2 Automated high-energy X-ray analysis, activates and detects gold atoms Efficient, effective and environmentally-friendly minerals analysis PhotonAssayTM technology CHRYSOS CORPORATION LIMITED | 33
Page 34
The next generations of Chrysos’ PhotonAssay analysis CHRYSOS CORPORATION LIMITED | 34 Supply chain resilience Reduced maintenance Improved performance ++ PhotonAssayTM Unit Development Development focus: PhotonAssayTM- XN: Even greater efficiency PhotonAssayTM - XC: The Aussie contender ■ Currently in testing and XC-beta design phase ■ Automation redesign with a high-performance robot executing the majority of sample handling, providing flexibility to reprogram operations and add additional analysis stages ■ Installed as an upgrade to ITK1 unit and operating successfully in Perth since May 2025. Max throughput increased to 83-84 jars p/h ■ Modular design with many key components available ‘off the shelf’ from commercial vendors ■ A new generation of PhotonAssayTM units, representing a smaller unit footprint, lighter weight for ease of installation, improved sample throughput and simplified maintenance ■ Strengthened unit economics with lower cost installation, reduced maintenance and higher capacity ■ Enhanced supply chain resilience with the introduction of an Australian-designed automation system ■ ITK’s first Perth unit has had its automation upgraded, demonstrating XN capability and the first complete XN was deployed to SGS Perth during 1H FY26
Page 35
Tailings disposal + water recovery PhotonAssayTM enables timely decision making and additional gold recovery Delivering tangible benefits for miners CHRYSOS CORPORATION LIMITED | 35 PhotonAssayTM is embedded in the mining value chain ■ Each year global miners are estimated to lose >$2.0 billion worth of recoverable gold ■ PhotonAssay TM provides miners with access to real-time data, helping to improve decision making through the value chain ■ Enabling the optimisation of processes to generate potential productivity gains The opportunity… Exploration Mine ROM Crushing StockpileGrindingMulti-stage concentration Gold room Smelting Product PhotonAssayTM Value Add Exploration Fast turnaround for mine planning and scheduling in-pitMine ROM Assay-supported blending between pit & processingCrushing Stockpile Stockpile sampling & optimised gold recovery Multi-stage concentration Reduction in process reagents & consumables Tailings + Water recovery Tailings grade monitoring Gold room All samples retained for QA/QC Product Buyer / seller assays Denotes PhotonAssayTM value add Source: S&P 2020 Global Gold Production
Page 36
Unit economics are the underlying strength behind Chrysos’ business Unit lifecycle & financial profile CHRYSOS CORPORATION LIMITED | 36 Manufacturing -9 Months • Detector station components integrated in Chrysos’ Adelaide facility, including integration of the system “smarts” detectors, electronics, and software • Heavy engineering and Linac components manufactured by Nuctech in China • Equipment shipped to installation site after Factory Acceptance Testing Deployment Lease End of life 8-12 weeks Key steps 1. Site readiness 2. Licensing 3. Cabin installation 4. Electrical and wiring 5. Integration testing 6. Site Acceptance Testing 5+5+5+5 year lease model Initial lease, renewal, recontract • Customer partnering throughout to empower miners and laboratories to attain maximum benefit from PhotonAssay TM and ensure customer satisfaction • PhotonAssayTM becomes critical infrastructure in the mine sites on which we operate, generally becoming the preferred method for gold analysis • Lease model allows Chrysos to maintain the PhotonAssayTM units in excellent working order throughout the lease and allows for replacement of key components in year 10 (~40% of initial capex) 20 Years Refurbishment or re-use Even at the point of 20 years of operation, various components of the system will remain fully usable. Offering the ability for refurbishment and re-use, balanced with obsolescence Lease Lease Lease -18 Months Long Lead Time Components orderedPrepayment ~A$100,000 Capital Costs ~20% of total capex on order ~20% of total capex at Factory Acceptance Testing pre-shipping Site Acceptance Testing (SAT) ~50% of total capex on SAT ~final 10% of capex paid SAT+12 months Majority of capital payments align with revenue generation (80% of capex paid either after, or within weeks of, revenue generation) Revenue Revenue made up of Minimum Monthly Assay Payments (MMAP) and Additional Assay Charges (AAC) providing fixed guaranteed revenue as well as upside exposure to macro markets and site-by-site sample growth Operating Costs Operating costs ~$475,000/annum2 1. Based on 3 year average revenue per unit of $1.95m and average capital cost of FY25 deployed units 2. Based on 3 year average operating costs Projected Lifetime Return more than $20m1 per unit Ordering
Page 37
Eric Ford – appointed June 2019 Non-Executive Director • 40 years of strategic, management, commercial, operating and engineering experience in resources and energy Kerry Gleeson – appointed July 2021 Non-Executive Director • Experienced executive and non- executive director in mining and associated industries • Qualified Australian and English Lawyer: M&A, debt & equity funding & commercialising technology Dirk Treasure Founding CEO & Managing Director • Metallurgist with a background in both technical and commercial mining aspects spanning 20 years in the industry • 7 years in novel metallurgical process development and commercialisation prior to becoming Chrysos’ founding CEO Brett Coventry Chief Financial Officer • Experienced in taking high growth technology start-ups from inception through to maturity • 20 years in various roles encompassing international expansion, capital raising and listing through IPO Rob Adamson – appointed June 2016 Founder & Non-Executive Chairman • 20+ years’ experience in mining and finance • Executive Chairman of RFC Ambrian Supported by a well-respected and tenured board Experienced leadership team Senior leadership team Board of Directors CHRYSOS CORPORATION LIMITED | 37 Greg Holt – appointed June 2023 Non-Executive Director • Senior executive with an international career spanning 40 years across logistics, industrial services, mining contracting and engineering industries Elisha Civil – appointed October 2025 Non-Executive Director • 20+ years’ experience across the mining, energy and infrastructure sectors, including senior leadership roles with ASX-listed and government-owned entities
Page 38
Financial Appendix
Page 39
Diversified global footprint — operations across ~12 tax jurisdictions CHRYSOS CORPORATION LIMITED | 39 Strong tax balance sheet underpinning international growth 1. Primarily driven by taxable profits in established international jurisdictions. What happened $6.6m deferred tax benefit Deferred tax benefits recognised on Australian tax losses, R&D credits and on transfers of PhotonAssay units overseas. International growth continued to expand the Group’s tax balance sheet. Cash impact Cash tax consistent with business growth Australian taxable income continues to be offset by carried-forward tax losses and R&D tax offsets. Cash tax reflecting the growth and profitability of international operations. Future periods Benefits unwind over time Deferred tax assets reverse as units depreciate, while new deployments create new differences. Cash tax to increase as Australian tax attributes are utilised and international operations continue to mature. $11.2m Closing net deferred tax asset $2.97m1 Current tax expense Deployed from Australia Transferred to subsidiary Temporary difference arises Deferred tax asset recognised Unwinds over asset life A strong tax balance sheet supporting the Group's high- growth trajectory, future earnings and sustainable cash tax profile.
Page 40
Component useful lives revised — change in accounting estimate effective 1 July 2026 CHRYSOS CORPORATION LIMITED | 40 Useful life reassessment extends the depreciation profile 1. Approximate weighted average across significant components. Change in accounting estimate under AASB 108, applied prospectively; prior periods not restated. What changed Component lives extended Automation: 5 → 10 years Linear accelerator: 10 → 15 years Shielding and housing: 20 → 25 years Other components: 10 → 15 years Weighted average life: ~10 → 15 years Accounting treatment Change in estimate Applied prospectively from 1 July 2026, with no restatement of FY2026 or comparatives and no change to asset carrying values. No cash flow or tax depreciation impact, and no impairment indicators. Modelling implications Lower charge from FY2027 FY2026 depreciation on deployed units was $18.6m (closing NBV $127.2m). Expected to reduce FY2027 depreciation by approximately $9m. 10 → 15 yrs Weighted average useful life¹ $18.6m FY26 deployed unit depreciation Longer asset lives reduce the annual depreciation charge from FY2027, with no change to cash flow or asset carrying values. Fleet operating history Maintenance and failure data Component-level review Useful lives extended Lower depreciation from FY2027